ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 12 Jul 2022
Last Updated on 12 Jul 2022
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Olaparib 100 mg and 150 mg tablets for treating germline BRCA-mutated, human epidermal growth factor receptor (HER2) negative, locally advanced or metastatic breast cancer in patients who have been previously treated with chemotherapy.

Subsidy status

Olaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022.

MAF assistance does not apply to olaparib 50 mg capsules or any formulations or strengths of talazoparib for treating BRCA-mutated, HER2-negative advanced breast cancer.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.


PARP inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer (12 Jul 22) PES Treatments for BRCA-mutated HER2-negative advanced breast cancer (Published 12 July 2022)